Search

Your search keyword '"Baylatry, Minh Tam"' showing total 11 results
Start Over Author "Baylatry, Minh Tam"
11 results on '"Baylatry, Minh Tam"'

1. Efficacy and safety of daratumumab in multiresistant immune‐mediated thrombotic thrombocytopenic purpura.

Author

Weisinger, Julia, Bouzid, Raïda, Ranta, Dana, Woaye‐Hune, Pascal, Cohen‐Aubart, Fleur, Gaible, Clotilde, Marjanovic, Zora, Corre, Elise, Joly, Anne‐Christine, Baylatry, Minh‐Tam, Joly, Berangère S., Veyradier, Agnès, and Coppo, Paul

Subjects
THROMBOTIC microangiopathies, DARATUMUMAB, MONOCLONAL antibodies, ACUTE diseases, CD38 antigen
Abstract

Summary: The immunosuppressive treatment of immune‐mediated thrombotic thrombocytopenic purpura (iTTP) in patients with intolerance or refractoriness to the B‐cell depleting monoclonal antibody rituximab remains debated. Daratumumab, a plasma cell‐directed monoclonal antibody targeting CD38, represents a therapeutic option, but data are scarce. The French Thrombotic Microangiopathies Reference Center conducted a nationwide survey on iTTP patients treated with daratumumab. Nine episodes from seven patients were identified. Treatment was administered for A Disintegrin And Metalloproteinase with ThromboSpondin‐1 motifs, 13th member (ADAMTS13) relapses while patients were otherwise in clinical response (N = 8), or during the acute phase of the disease following rituximab intolerance (N = 1). Patients have received a median of three previous therapeutic lines. ADAMTS13 activity improved in eight cases following daratumumab administration, including three cases where ADAMTS13 normalized. ADAMTS13 relapses occurred in three patients; in two cases, retreatment with daratumumab was successful. Median ADAMTS13 relapse‐free survival was not reached; 12‐month ADAMTS13 relapse‐free survival was 56%. Daratumumab‐related adverse events occurred in five cases and were non‐severe infusion‐related reactions in all cases. These results suggest that daratumumab may be an effective treatment option for iTTP patients with intolerance or refractoriness to rituximab. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study

Author

Picod, Adrien, Bonnin, Agnès, Battipaglia, Giorgia, Giannotti, Federica, Ruggeri, Annalisa, Brissot, Eolia, Malard, Florent, Médiavilla, Clémence, Belhocine, Ramdane, Vekhoff, Anne, Gueye, Mor Sény, Lapusan, Simona, Adaeva, Rosa, Isnard, Françoise, Legrand, Ollivier, Baylatry, Minh-Tam, Joly, Anne-Christine, Labopin, Myriam, Duléry, Rémy, and Mohty, Mohamad

Published
2018
Full Text
View/download PDF

5. Efficacy of subcutaneous preemptive rituximab in immune‐mediated thrombotic thrombocytopenic purpura: Experience from the first 12 cases

Author

Delrue, Maxime, primary, Baylatry, Minh Tam, additional, Joly, Anne‐Christine, additional, Corre, Elise, additional, Marjanovic, Zora, additional, El‐Khoury‐Hanna, Noujoud, additional, Féger, Frédéric, additional, Suner, Ludovic, additional, Veyradier, Agnès, additional, Stépanian, Alain, additional, and Coppo, Paul, additional

Published
2020
Full Text
View/download PDF

6. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria

Author

Rubio, Marie-Thérèse, Battipaglia, Giorgia, Malard, Florent, Rubio, Marie Therèse, Ruggeri, Annalisa, Mamez, Anne Claire, Brissot, Eolia, Giannotti, Federica, Dulery, Remy, Joly, Anne Christine, Baylatry, Minh Tam, Kossmann, Marie Jeanne, Tankovic, Jacques, Beaugerie, Laurent, Sokol, Harry, Mohty, Mohamad, University of Naples Federico II, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Universités (COMUE), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Service de Pharmacie [CHU Saint Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Laboratoire des biomolécules (LBM UMR 7203), Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Département de Chimie - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Chimie Moléculaire de Paris Centre (FR 2769), Institut de Chimie du CNRS (INC)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris sciences et lettres (PSL), This study was supported by educational grants from the 'Association for Training, Education and Research in Hematology, Immunology and Transplantation' (ATERHIT, Nantes, France)., Service d'Hématologie [CHRU Nancy], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Sorbonne Université (SU), Université de Lorraine (UL), CHU Saint-Antoine [APHP], Chimie Moléculaire de Paris Centre (FR 2769), École normale supérieure - Paris (ENS Paris)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-ESPCI ParisTech-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-ESPCI ParisTech-Centre National de la Recherche Scientifique (CNRS)-Département de Chimie - ENS Paris, École normale supérieure - Paris (ENS Paris)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), PSL Research University (PSL), University of Naples Federico II = Università degli studi di Napoli Federico II, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Département de Chimie - ENS Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Gestionnaire, Hal Sorbonne Université, Battipaglia, G., Malard, F., Rubio, M. T., Ruggeri, A., Mamez, A. C., Brissot, E., Giannotti, F., Dulery, R., Joly, A. C., Baylatry, M. T., Kossmann, M. J., Tankovic, J., Beaugerie, L., Sokol, H., and Mohty, M.

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, Constipation, medicine.medical_treatment, Hematopoietic stem cell transplantation, Drug resistance, Gastroenterology, [SHS]Humanities and Social Sciences, Perioperative Care/methods, 0302 clinical medicine, fluids and secretions, Hematologic Neoplasms/complications/diagnosis/therapy, Retrospective Studie, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Drug Resistance, Multiple, Bacterial, Transplantation, Homologou, ComputingMilieux_MISCELLANEOUS, allogeneic, Hematopoietic Stem Cell Transplantation, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Enema, Fecal Microbiota Transplantation, Clostridium difficile, Middle Aged, 3. Good health, Diarrhea, Treatment Outcome, Hematologic Neoplasms, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, medicine.symptom, Human, Adult, medicine.medical_specialty, Article, Perioperative Care, 03 medical and health sciences, Internal medicine, medicine, Humans, Transplantation, Homologous, hematologic, Hematologic Neoplasm, hematopoietic, Feces, Aged, Retrospective Studies, business.industry, Fecal Microbiota Transplantation/methods, Dysbiosis/etiology/therapy, Dysbiosi, Transplantation, malignancies, Dysbiosis, business, Stem Cell Transplantation, 030215 immunology, transplantation
Abstract

International audience; Fecal microbiota transplantation is an effective treatment in recurrent Clostridium difficile infection. Promising results to eradicate multidrug-resistant bacteria have also been reported with this procedure, but there are safety concerns in immunocompromised patients. We report results in ten adult patients colonized with multidrug-resistant bacteria, undergoing fecal microbiota transplantation before (n=4) or after (n=6) allogeneic hematopoietic stem cell transplantation for hematologic malignancies. were obtained from healthy related or unrelated donors. Fecal material was delivered either by enema or via nasogastric tube. Patients were colonized or had infections from either carbapenemase-producing bacteria (n=8) or vancomycin-resistant enterococci (n=2). Median age at fecal microbiota transplantation was 48 (range, 16-64) years. Three patients needed a second transplant from the same donor due to initial failure of the procedure. With a median follow up of 13 (range, 4-40) months, decolonization was achieved in seven of ten patients. In all patients, fecal micro-biota transplantation was safe: one patient presented with constipation during the first five days after FMT and two patients had grade I diarrhea. One case of gut grade III acute graft-versus-host disease occurred after fecal microbiota transplantation. In patients carrying or infected by multidrug-resistant bacteria, fecal microbiota transplantation is an effective and safe decolonization strategy, even in those with hematologic malignancies undergoing hematopoietic stem cell transplantation.

Published
2019
Full Text
View/download PDF

7. Fecal microbiota transplantation before or after allogeneic hematopoietic transplantation in patients with hematologic malignancies carrying multidrug-resistance bacteria

Author

Battipaglia, Giorgia, primary, Malard, Florent, additional, Rubio, Marie Therèse, additional, Ruggeri, Annalisa, additional, Mamez, Anne Claire, additional, Brissot, Eolia, additional, Giannotti, Federica, additional, Dulery, Remy, additional, Joly, Anne Christine, additional, Baylatry, Minh Tam, additional, Kossmann, Marie Jeanne, additional, Tankovic, Jacques, additional, Beaugerie, Laurent, additional, Sokol, Harry, additional, and Mohty, Mohamad, additional

Published
2019
Full Text
View/download PDF

11. A combination of 5-azacytidine and nivolumab is a potentially effective rescue therapy in relapsed/refractory AITL.

Author

Ricard L, Cervera P, Stocker N, Corre E, Van de Wyngaert Z, Banet A, Marjanovic Z, Dulery R, Bravetti C, Joly AC, Baylatry MT, and Coppo P

Subjects
Humans, Female, Male, Aged, Middle Aged, Neoplasm Recurrence, Local drug therapy, Lymphoma, T-Cell, Peripheral drug therapy, Lymphoma, T-Cell, Peripheral mortality, Treatment Outcome, Aged, 80 and over, Drug Resistance, Neoplasm, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors adverse effects, Nivolumab therapeutic use, Azacitidine therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects
Abstract

Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by a T follicular helper cell phenotype expressing PD-1 (programmed cell death-1). AITL exhibits a poor response to conventional chemotherapy, with a median 5-year overall survival of 44% and a progression-free survival of 32%. Relapse is common, resulting in a median overall survival of 6 months. Recurrent mutations are detected in genes regulating DNA methylation, including TET2, DNMT3A, and IDH2 variants, along with the prevalent RHOA G17V mutation. In this context, patients treated with the hypomethylating agent 5-azacytidine achieved overall response and complete response rates of 75% and 41%, respectively. We hypothesized that targeted therapies combining anti-PD-1 checkpoint blockers with hypomethylating agents could be efficient in AITL patients and less toxic than standard chemotherapy., Methods: Here, we report the efficacy of a regimen combining 5-azacytidine and nivolumab in nine relapsed or refractory AITL patients., Results: This regimen was well-tolerated, especially in elderly patients. The overall response rate was 78%, including four partial responses (44%) and three complete responses (33%). Allogeneic hematopoietic stem cell transplantation was performed in two patients who reached complete response., Discussion: These preliminary favorable results may serve as a basis for further investigation in prospective studies., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Ricard, Cervera, Stocker, Corre, Van de Wyngaert, Banet, Marjanovic, Dulery, Bravetti, Joly, Baylatry and Coppo.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results